Nuo Therapeutics Signs Exclusive Distribution Deal with Smith+Nephew
Nuo Therapeutics, Inc. (OTCQB: AURX) has recently made headlines with the announcement of a significant private label distribution agreement with Smith+Nephew, a leader in medical technology. This partnership marks an exciting new chapter for Nuo, as it strategically positions itself within the advanced wound care market.
Understanding the Distribution Agreement
Under the terms of this agreement, Smith+Nephew will promote and distribute the CENTRIO Platelet-Rich Plasma System, a branded version of Nuo's innovative Aurix System. This agreement allows Nuo Therapeutics to remain in charge of manufacturing the product while ensuring that the Aurix brand continues to be available in the market under their full control.
The Significance of the Collaboration
David Jorden, Chief Executive and Financial Officer of Nuo, expressed his enthusiasm about the collaboration, stating, "This exclusive private label distribution agreement with Smith+Nephew is a significant development for Nuo. We believe this partnership holds immense potential, particularly in the realm of chronic wound management, helping countless patients who face non-healing wounds." He highlighted the advantages of Smith+Nephew’s market presence and resources, which are expected to heighten awareness and adoption of autologous PRP therapies.
Smith+Nephew’s Perspective
Vincent Fath, Senior Vice President and General Manager at Smith+Nephew, also shared his excitement regarding the agreement. He noted that Smith+Nephew looks forward to introducing CENTRIO PRP technology to enhance treatment options for patients in need of advanced wound care during the upcoming year. Planning such collaborations is a testament to their dedication to improving patient care through innovative solutions.
Growing Market for PRP Therapies
The announcement comes on the heels of increasing interest in Platelet-Rich Plasma therapies. The Aurix System is designed to harness the body's natural healing properties, making it a valuable asset in managing a range of wound types. As Nuo responds to the changing landscape of healthcare, they aim to build long-term success through strategic collaborations like the one with Smith+Nephew.
Nuo’s Commitment to Innovative Solutions
According to Jorden, Nuo Therapeutics has been on a promising path since the establishment of mandated coverage for PRP therapies in chronic wound management. He underscored the dedication of the Nuo team in adapting to ongoing changes in the advanced wound care market and is optimistic about future advancements the company hopes to share.
Key Financial Aspects of the Agreement
As part of the exclusive agreement, Nuo has secured an upfront distribution fee from Smith+Nephew for the rights to CENTRIO for an initial term of five years. They will also benefit from minimum purchase commitments at established transfer pricing. Importantly, Nuo could attain further reimbursement milestone payments contingent on satisfying specific coverage requirements.
About Nuo Therapeutics
Nuo Therapeutics, Inc. is dedicated to pioneering biodynamic therapies that leverage the body’s innate healing mechanisms. The Aurix System exemplifies their commitment to enhancing patient recovery and management of wounds, demonstrating how innovative medical solutions can change the landscape of healthcare.
Frequently Asked Questions
What is the nature of the agreement between Nuo Therapeutics and Smith+Nephew?
The agreement is an exclusive private label distribution deal for the CENTRIO Platelet-Rich Plasma System.
What does Nuo Therapeutics manufacture?
Nuo Therapeutics manufactures the Aurix System, which focuses on harnessing a patient’s regenerative abilities for wound management.
How long will the distribution agreement last?
The agreement has an initial term of five years with potential for renewal based on performance.
What market are Nuo and Smith+Nephew targeting?
They are focusing on the United States wound care market to enhance treatment options for chronic wounds.
How can this partnership benefit patients?
This collaboration aims to improve patient outcomes by expanding access to advanced wound care therapies and enhancing recovery options.
